Age: 16.0
Sex: M
Vaccine: HPV4
Symptoms: Head discomfort, Loss of personal independence in daily activities, Palpitations, Postural orthostatic tachycardia syndrome, Syncope
Clinical narrative: Postural Orthostatic Tachycardia (POTS); dysautonomia; he has difficulty functioning in his daily life. His high school and college performance suffered because of his symptoms, and he now must attend college from  home; Information has been received from a lawyer regarding a case in litigation and refers to a 17-year-old male patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported.   On an unknown date, the patient was vaccinated with first and second dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) intramuscular injection, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided). After receiving the second dosage of the vaccine, the patient experienced extreme exhaustion, dizziness, fainting spells, brain fog, heart palpitations, head pressure, and difficulty concentrating. As the months progressed, so did patient's symptoms. He was seen by multiple physicians and specialists for his complaints, one of which discussed the connection between quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) and postural orthostatic tachycardia syndrome (POTS). As a result of his post- quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) symptoms, patient had been unable to engage in activities that a young person his age would normally enjoy, and he had difficulty functioning in his daily life. His high school and college performance suffered because of his symptoms, and he now must attend college from home. Based upon his chronic and severe post- quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) symptoms, patient had been diagnosed with POTS and dysautonomia. As a proximate result of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL), the patient had suffered and continued to suffer severe and permanent physical injuries, and associated symptomology and has suffered severe and permanent emotional injuries, including pain and suffering. Patient also had a substantial fear of suffering additional and ongoing harms, including but not limited to now being at an increased risk of cancer, and future symptoms and harms associated with his autoimmune disease and other injuries caused by Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL). As a direct and proximate result of his Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL)-induced injuries, patient had suffered and continued to suffer economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity and he would continue to incur these losses and expenses in the future. At the time of reporting, the patient had not recovered from the events.  The reporter considered all the events to be related to quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL).   The reporter considered the event POTS and dysautonomia to be disability events.